2017 Health for Humanity Report
Better Health for All
Better Health for All
Better Health for All
Better Health for All

Research & Development

The world’s major global health challenges call for products and practices designed specifically to address the real world needs of people living in underserved regions of the world. Failing to address these challenges while products are still in development can greatly hamper even the most ambitious efforts to promote access once a product is approved. In recognizing this critical need, we established a dedicated R&D team within GPH.

GPH R&D is focused on fighting health challenges in resource-limited settings, including but not limited to HIV, tuberculosis, neglected tropical diseases (NTDs), maternal, newborn and child health. Benefiting from the clinical research, product development and commercialization expertise across our three business segments, GPH works on innovative solutions for the developing world, specifically designed for places in need and appropriate for local contexts. This includes our work on developing dramatically simpler treatment regimens for drug-resistant tuberculosis, exploring prevention and treatment options for NTDs such as dengue, and efforts to develop a “global vaccine” that could prevent a wide range of viral strains responsible for the HIV pandemic. Recognizing the tremendous potential of vaccines to address global health challenges, Janssen's dedicated vaccines R&D organization (which is focused on HIV, influenza, Respiratory Syncytial Virus [RSV], Zika, Ebola, and Marburg among others) partners closely with our GPH R&D group in executing programs in Sub-Saharan Africa.

We focus on both internal and external innovation and proactively seek partnerships to advance shared goals, leveraging the power of Johnson & Johnson strategic relationships, networks and resources, such as JLABS, Innovation Centers, and QuickFire Challenges. As one example of our innovation model to provide access to medicine in places where it is needed, JLABS launched the Latin America QuickFire Challenge. The goal was to identify and help early-stage companies focusing on promising science in the region. The winning company received space at JLABS to work through a local university in Brazil on a therapeutic to address the Zika virus.

To advance science, including for meeting the public health needs of the developing world, we open our compound libraries and provide our partners access to the research capabilities of Johnson & Johnson. This underscores our commitment to accelerate the pace of innovation, and to broaden our reach and deepen our impact. For more information, see Clinical Data Sharing in the Ethics & Transparency section.

You are leaving jnj.com and entering a third party site. This link is provided for your convenience, and Johnson & Johnson disclaims liability for content created or maintained by third parties. Continue